0.0189
+0.0069
+(57.50%)
As of January 24 at 3:00:00 PM EST. Market Open.
Breakdown
TTM
7/31/2023
7/31/2022
7/31/2021
3/31/2021
Total Revenue
2,332.7970
1,029.9890
1,070.8040
--
--
Operating Expense
3,146.8280
3,080.6850
5,817.0490
3,864.8860
77.4130
Operating Income
-814.0310
-2,050.6960
-4,746.2450
-3,864.8860
-77.4130
Net Non Operating Interest Income Expense
-141.0180
-153.2240
-67.7420
-15.0050
0.0250
Other Income Expense
-606.3860
-186.4910
-5,682.2150
12.6740
-213.2600
Pretax Income
-1,561.4350
-2,390.4110
-10,496.2020
-3,867.2170
-290.6480
Net Income Common Stockholders
-1,561.4350
-2,390.4110
-10,496.2020
-3,867.2170
-290.6480
Diluted NI Available to Com Stockholders
-1,561.4350
-2,390.4110
-10,496.2020
-3,867.2170
-290.6480
Basic EPS
-0.01
-0.01
-0.06
-0.03
-0.03
Diluted EPS
-0.01
-0.01
-0.06
-0.03
-0.03
Basic Average Shares
214,633.9480
191,298.2570
185,636.8550
125,189.5970
9,688.2670
Diluted Average Shares
214,633.9480
191,298.2570
185,636.8550
125,189.5970
9,688.2670
Total Operating Income as Reported
659.8040
-28.0330
497.1510
--
--
Total Expenses
3,146.8280
3,080.6850
5,817.0490
3,864.8860
77.4130
Net Income from Continuing & Discontinued Operation
-1,561.4350
-2,390.4110
-10,496.2020
-3,867.2170
-290.6480
Normalized Income
-978.7580
-2,217.3020
-4,941.5640
-3,848.0690
-77.3880
Interest Income
--
--
--
31.8220
0.0250
Interest Expense
141.0180
153.2240
67.7420
15.0050
--
Net Interest Income
-141.0180
-153.2240
-67.7420
-15.0050
0.0250
EBIT
-1,420.4170
-2,237.1870
-10,428.4600
-3,852.2120
-77.4130
EBITDA
-1,086.3630
-1,941.1410
-10,162.0620
-3,782.3560
-77.1080
Reconciled Depreciation
334.0540
296.0460
266.3980
69.8560
0.3050
Net Income from Continuing Operation Net Minority Interest
-1,561.4350
-2,390.4110
-10,496.2020
-3,867.2170
-290.6480
Total Unusual Items Excluding Goodwill
-582.6770
-173.1090
-5,554.6380
-19.1480
-213.2600
Total Unusual Items
-582.6770
-173.1090
-5,554.6380
-19.1480
-213.2600
Normalized EBITDA
-503.6860
-1,768.0320
-4,607.4240
-3,763.2080
136.1520
3/31/2021 - 3/1/2022
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
RBSH Rebus Holdings, Inc.
0.0001
0.00%
ZHCLF Zenith Capital Corp.
0.0001
-99.90%
BETRF BetterLife Pharma Inc.
0.1140
-5.00%
WSNAF Wesana Health Holdings Inc.
0.0540
-14.29%
IBO Impact BioMedical Inc.
2.0000
+13.06%
MDMA.CN Pharmala Biotech Holdings Inc.
0.2350
0.00%
RNA Avidity Biosciences, Inc.
31.63
+6.61%
CRDF Cardiff Oncology, Inc.
3.4300
+0.59%
MNMD Mind Medicine (MindMed) Inc.
6.88
-1.65%
CHRO Channel Therapeutics Corporation
2.0332
-16.67%